Therefore, these findings suggest that choline and parecoxib sodium may both inhibit the HMGB1/TLR4/NF-κB signaling pathway and may be used together for the treatment of neuropathic pain, which remains a great clinical challenge. The gene discussed is TLR4; the disease is neuropathic pain.